医疗特长：主要从事肿瘤与血管疾患的微创介入治疗，特别是对原发性 肝癌、转移性肝癌、肺癌、胆管癌、胰腺癌、膀胱癌、盆腔肿 瘤的介入诊疗（包括局部肿瘤的化疗栓塞、氩氦刀冷冻、射频、 微波消融、粒子与支架植入、药盒埋置、全身规范化疗和分子靶向治疗）等方面也积累了较丰富的诊疗经验。一、本人第一作者或通讯作者身份发表SCI10余篇，主要代表作如下：(1) Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC, Ther Adv Med Oncol.(2) Pseudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization.（3）Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resection，BMC Cancer.（4）A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer, Transl Lung Cancer Res,.(5) A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer, Transl Lung Cancer Res.(6)Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers, BMC Cancer.(7) Development and validation of a nomogram for predicting survival time and makingtreatment decisions for clinical stage IA NSCLC based on the SEER database, Front Med.(8)Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy, Front Oncol.(9) Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection, Cancer Commun (Lond).(10) Comparison between microwave ablation and lobectomy for stage I non-small cell lung cancer: a propensity score analysis, Int J Hyperthermia.二、本人主持和参与多项国家及省市级基金，具体如下：1.广东省医学科学技术研究基金，TIGIT介导的免疫逃逸调控非小细胞肺癌消融后复发机制研究。2.国家自然基金面上项目，射频消融联合盐酸灌注治疗不可切除大肝癌的基础和临床研究。3.广州市民生科技计划，基于移动互联网的恶性肿瘤精准服务平台关键技术研发与运用。4.国家自然科学基金委员会，青年项目；81701799；耐久霉素FPDuramycin-PET凋亡显像对软组织肉瘤冷冻消融精准功能影像评估的分子机制。三、社会任职，具体如下：广东省器官医学与技术学会肝癌多学科综合治疗专业委员会 常务委员广东省中西医结合学会肿瘤介入治疗专业委员会 委员广东省基层医药学会肝癌防治专业委员会 委员广东省抗癌协会肿瘤微创介入专业委员会青年委员会 委员